Citigroup
ANTH

Citigroup’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Citigroup’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-14
Closed – – 7616
2017
Q1 		$0 Sell
14
-4,780
-100% -$22.6K ﹤0.01% 7443
2016
Q4 		$25K Buy
4,794
+3,555
+287% +$61.5K ﹤0.01% 6453
2016
Q3 		$31K Buy
1,239
+132
+12% +$3.33K ﹤0.01% 5974
2016
Q2 		$27K Sell
1,107
-3,608
-77% -$102K ﹤0.01% 5990
2016
Q1 		$136K Buy
4,715
+3,450
+273% +$93.6K ﹤0.01% 5439
2015
Q4 		$47K Buy
1,265
+1,145
+954% +$50.5K ﹤0.01% 5997
2015
Q3 		$6K Buy
120
+36
+43% +$2.52K ﹤0.01% 6682
2015
Q2 		$6K Buy
+84
New +$3.89K ﹤0.01% 6703
2015
Q1 		– Sell
-185
Closed -$2K – 7593
2014
Q4 		$2K Sell
185
-2,003
-92% -$29.1K ﹤0.01% 6901
2014
Q3 		$34K Sell
2,188
-31
-1% -$652 ﹤0.01% 5568
2014
Q2 		$60K Buy
2,219
+31
+1% +$765 ﹤0.01% 5040
2014
Q1 		$59K Hold
2,188
– – ﹤0.01% 5391
2013
Q4 		$54K Hold
2,188
– – ﹤0.01% 5683
2013
Q3 		$70K Sell
2,188
-2,375
-52% -$73.7K ﹤0.01% 5012
2013
Q2 		$135K Buy
+4,563
New +$170K ﹤0.01% 4600

Other funds holding ANTH

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Citigroup's ANTH Position: Q2 2017 in Review

Citigroup sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2017, closing a stake of 14 shares.

Citigroup first reported a position in ANTH in Q2 2013 and held it in 15 quarters. The position peaked at $136K in Q1 2016. 40 funds tracked by Wall St. Rank hold ANTH as of Q2 2017.

  • Citigroup reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Citigroup sold 14 Anthera Pharmaceuticals, Inc. shares in Q2 2017.
  • Citigroup first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
  • Citigroup's Anthera Pharmaceuticals, Inc. position peaked at $136K in Q1 2016.
  • 40 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2017.

Based on Citigroup's 13F filing for Q2 2017, filed 11 Aug 2017.